Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9H6P5

UPID:
TASP1_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9H6P5; B7Z690; B7Z963; Q5TDU9; Q9BQN0; Q9NQ08; Q9NTS6; Q9NXJ2

BACKGROUND:
The enzyme Threonine aspartase 1, with the unique identifier Q9H6P5, is a key player in the activation of KMT2A/MLL1 and KMT2D/MLL2, crucial for gene expression regulation. Its involvement in the activation of substrates that control HOXA genes and cell cycle regulators, including CCNA1, CCNB1, CCNE1, and CDKN2A, positions it as a central figure in cellular growth and differentiation.

THERAPEUTIC SIGNIFICANCE:
Threonine aspartase 1's role in Suleiman-El-Hattab syndrome, characterized by developmental and physical anomalies, points to its significance in human health. The disease's link to this protein provides a compelling case for its study in the context of therapeutic development. Understanding the role of Threonine aspartase 1 could open doors to potential therapeutic strategies, marking a significant step forward in treating genetic diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.